We investigated panobinostat 40 mg three times weekly in 35 adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Overall response rate and complete response were 17.1% and 11.4%, respectively. Median progression-free survival (PFS) and overall survival were 2.4 and 7.6 months, respectively. Calculated 12, 24 and 36 months PFS were 26%, 11% and 11%, respectively. Four patients who achieved a sustained CR, continued receiving panobinostat for an overall period of 44, 48, 50, 62 months. Thrombocytopenia grade 3 (5 patients) and 4 (24 patients) represented the main toxic effect, causing dose reduction or treatment suspension in 19 patients. Genomic analysis was unable to identify any relationship between mutations and response; TP53 mutation appeared not to impact the clinical outcome. Overall, panobinostat has a modest activity in R/R DLBCL patients, however it can induce very long lasting responses in some cases. Thrombocytopenia frequently limits the use of this agent.

Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

Evangelista, Andrea;Ciccone, Giovannino;Zanni, Manuela;Ladetto, Marco;Chiappella, Annalisa;Cavallo, Federica;
2018

Abstract

We investigated panobinostat 40 mg three times weekly in 35 adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Overall response rate and complete response were 17.1% and 11.4%, respectively. Median progression-free survival (PFS) and overall survival were 2.4 and 7.6 months, respectively. Calculated 12, 24 and 36 months PFS were 26%, 11% and 11%, respectively. Four patients who achieved a sustained CR, continued receiving panobinostat for an overall period of 44, 48, 50, 62 months. Thrombocytopenia grade 3 (5 patients) and 4 (24 patients) represented the main toxic effect, causing dose reduction or treatment suspension in 19 patients. Genomic analysis was unable to identify any relationship between mutations and response; TP53 mutation appeared not to impact the clinical outcome. Overall, panobinostat has a modest activity in R/R DLBCL patients, however it can induce very long lasting responses in some cases. Thrombocytopenia frequently limits the use of this agent.
1
7
Diffuse large B-cell lymphoma; genomic; panobinostat; relapsed/refractory; Hematology; Oncology; Cancer Research
Zaja, Francesco*; Salvi, Flavia; Rossi, Maura; Sabattini, Elena; Evangelista, Andrea; Ciccone, Giovannino; Angelucci, Emanuele; Gaidano, Gianluca; Zanni, Manuela; Ladetto, Marco; Chiappella, Annalisa; Vitolo, Umberto; Zinzani, Pier Luigi; Califano, Catello; Tucci, Alessandra; Patti, Caterina; Pileri, Stefano A.; Lenti, Valentina; Piccaluga, Pier Paolo; Cavallo, Federica; Volpetti, Stefano; Perali, Giulia; Assouline, Sarit; Mann, Koren Kathleen; Morin, Ryan; Alcaide, Miguel; Bushell, Kevin; Fanin, Renato; Levis, Alessandro
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1681025
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 5
social impact